Vaccine News and Research

Latest Vaccine News and Research

Teen girls' beliefs regarding HPV vaccine not linked to subsequent sexual behaviors

A new study may alleviate concerns that the human papillomavirus (HPV) vaccine leads to either the initiation of sex or unsafe sexual behaviors among teenage girls and young women.

3 Feb 2014

Keystone Symposia to convene conference focusing on the science of malaria eradication

Keystone Symposia, in collaboration with MESA (Malaria Eradication Scientific Alliance), is convening its first conference in Mexico – on "The Science of Malaria Eradication" at the Fiesta Americana Hotel in Merida, Yucatan. The four-day conference begins Sunday evening, February 2, 2014 and is part of the Keystone Symposia Global Health Series, supported by the Bill & Melinda Gates Foundation, which has also funded travel awards for investigators from malaria-endemic countries to attend. The conference will gather experts from 37 countries.

31 Jan 2014

Novel approaches could lead researchers to develop new vaccine for East Coast fever, malaria

The Nairobi-based International Livestock Research Institute announced today that a global consortium supported by the Bill & Melinda Gates Foundation has been formed to develop a new vaccine against a disease that's devastating cattle herds in sub-Saharan Africa. This highly advanced cattle vaccine project could also help malaria and cancer research in humans.

31 Jan 2014

Vaccine to treat precancerous cervical lesions triggers immune cell response

Preliminary results of a small clinical trial show that a vaccine used to treat women with high-grade precancerous cervical lesions triggers an immune cell response within the damaged tissue itself.

30 Jan 2014

NIBIO signs collaboration agreement for clinical development of new mucosal TB vaccines

Japan's National Institute of Biomedical Innovation ("NIBIO"), Aeras and Create Vaccine Company, Ltd ("CREATE") announce today that they signed a collaboration agreement on December 26, 2013, on the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO's human parainfluenza type-2 (rhPIV2) vector technology.

27 Jan 2014

TSRI professor wins 2014 Wolf Prize in chemistry

Chi-Huey Wong, professor of chemistry at The Scripps Research Institute (TSRI), has won the 2014 Wolf Prize in Chemistry for his pioneering contributions to the synthesis of compounds vitally important to biology and medicine.

25 Jan 2014

Clinical trial of experimental vaccine targets cancer stem cells in patients with recurrent brain tumor

An early-phase clinical trial of an experimental vaccine that targets cancer stem cells in patients with recurrent glioblastoma multiforme, the most common and aggressive malignant brain tumor, has been launched by researchers at Cedars-Sinai's Department of Neurosurgery, Johnnie L. Cochran, Jr. Brain Tumor Center and Department of Neurology.

25 Jan 2014

OBGYN.net to present new research and topics related to cervical health

UBM Medica US announces that OBGYN.net, a leading online community for medical professionals specializing in women's health, will present new research and topics over the coming weeks related to cervical cancer and cervical health in honor of January being Cervical Health Awareness Month.

23 Jan 2014

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

Inovio Pharmaceuticals, Inc. today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 (IL-33), that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines in a preclinical study.

23 Jan 2014

CWRU researchers receive NIAID grant to conduct HIV research and clinical trials

AIDS researchers from Case Western Reserve University and University Hospitals Case Medical Center have received a seven-year funding award from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health.

23 Jan 2014

Personalized vaccine therapy contributes to increased survival rate in IL2-treated metastatic melanoma

Metastatic melanoma has a poor prognosis, but treatment with high-dose interleukin-2 (IL2) can extend survival. Now, a combination of IL2 therapy and activation of patients' immune systems using personalized vaccines made from their own tumor cells has been shown to improve survival rates even more than IL2 alone, according to a new article in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

23 Jan 2014

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

The University of Texas MD Anderson Cancer Center will collaborate with Johnson & Johnson Innovation, LLC, and its affiliate Janssen Biotech, Inc., to develop immunology-based cancer treatments through the MD Anderson Moon Shots Program immunotherapy platform.

23 Jan 2014

NPS MedicineWise urges parents to ensure that children's vaccinations are up to date

Following a recent spate of measles cases being reported in a number of Australian states, NPS MedicineWise is reminding parents to check whether their children’s immunisations are up to date before they head back to school next week.

22 Jan 2014

Swedish study confirms H1N1 vaccinations show increased risk of narcolepsy in children, adolescents

Pandemrix is an influenza vaccination, created in 2009 to combat H1N1, known as Swine Flu. Now, a team of Swedish clinicians testing the vaccine for links to immune-related or neurological diseases have linked Pandemrix to an increased risk of narcolepsy in young adults.

21 Jan 2014

Study provides insight into physician recommendations to improve HPV vaccination

The risk of developing cervical cancer can be significantly decreased through human papillomavirus vaccination. Despite calls from leading health and professional organizations for universal vaccination for girls ages 11 and 12, the most recently published national data indicate that only 14.5 percent of 11- and 12-year-old girls have received at least one dose of the HPV vaccine and 3 percent have completed the three-dose series. A new Moffitt Cancer Center study provides insight into physician recommendations, one important factor that may contribute to these low levels of uptake.

21 Jan 2014

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Vivaldi Biosciences Inc., a clinical-stage biotechnology company developing live attenuated influenza vaccines against seasonal and pandemic influenza, today announced that it has signed a Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, to generate and evaluate in preclinical studies LAIV candidates against influenza A(H7N9).

21 Jan 2014

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Agenus Inc., a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, announced that Phase 2 results of Prophage G-200 vaccine in recurrent patients with glioblastoma multiforme were hailed as 'exciting' and a 'very promising therapy' in an editorial published in Neuro-Oncology, the leading journal of the Society of Neuro-Oncology.

21 Jan 2014

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

Alexion Pharmaceuticals today announced that the U.S. Food and Drug Administration has granted an orphan drug designation to Soliris (eculizumab), a first-in-class terminal complement inhibitor, for the prevention of delayed graft function in renal transplant patients.

21 Jan 2014

First Edition: January 21, 2014

Today's headlines include news on the health law's implementation at both the federal and state levels.

21 Jan 2014

Researchers develop 3 hypoallergenic variants of Pru p 3 protein

A research conducted by the Centre for Plant Biotechnology and Genomics (UPM-INIA) and led by Araceli Díaz Perales has studied the allergy to peach, the most common food allergy, and the Pru p 3 protein. As a result of this research work, they have developed three hypoallergenic variants of this protein. All can be good candidates for the usage of specific immunotherapy for peach allergy and also can be used as a vaccine.

20 Jan 2014

Vaccine News and Research

Latest Vaccine News and Research

Teen girls' beliefs regarding HPV vaccine not linked to subsequent sexual behaviors

Keystone Symposia to convene conference focusing on the science of malaria eradication

Novel approaches could lead researchers to develop new vaccine for East Coast fever, malaria

Vaccine to treat precancerous cervical lesions triggers immune cell response

NIBIO signs collaboration agreement for clinical development of new mucosal TB vaccines

TSRI professor wins 2014 Wolf Prize in chemistry

Clinical trial of experimental vaccine targets cancer stem cells in patients with recurrent brain tumor

OBGYN.net to present new research and topics related to cervical health

Inovio Pharmaceuticals unveils new DNA-based cytokine immune activator

CWRU researchers receive NIAID grant to conduct HIV research and clinical trials

Personalized vaccine therapy contributes to increased survival rate in IL2-treated metastatic melanoma

MD Anderson collaborates with Johnson & Johnson to develop immunology-based cancer treatments

NPS MedicineWise urges parents to ensure that children's vaccinations are up to date

Swedish study confirms H1N1 vaccinations show increased risk of narcolepsy in children, adolescents

Study provides insight into physician recommendations to improve HPV vaccination

Vivaldi Biosciences inks agreement with NIAID to evaluate LAIV candidates against influenza A

Agenus' Prophage vaccine Phase 2 study hailed in Neuro-Oncology journal

Alexion's Soliris gets FDA orphan drug designation for DGF prevention in renal transplant patients

First Edition: January 21, 2014

Researchers develop 3 hypoallergenic variants of Pru p 3 protein

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in